Marshall Wace LLP Sells 47,995 Shares of InflaRx (NASDAQ:IFRX)

Marshall Wace LLP reduced its holdings in shares of InflaRx (NASDAQ:IFRX) by 58.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,824 shares of the company’s stock after selling 47,995 shares during the quarter. Marshall Wace LLP owned approximately 0.06% of InflaRx worth $59,000 as of its most recent SEC filing.

Separately, Ikarian Capital LLC grew its position in InflaRx by 2.4% during the first quarter. Ikarian Capital LLC now owns 704,987 shares of the company’s stock worth $1,086,000 after buying an additional 16,383 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of InflaRx in a research note on Wednesday, September 25th.

InflaRx Trading Up 3.4 %

NASDAQ IFRX opened at $1.51 on Monday. InflaRx has a 1-year low of $1.14 and a 1-year high of $2.64. The firm has a market cap of $88.91 million, a PE ratio of -1.94 and a beta of 1.57. The stock has a 50-day moving average of $1.49 and a 200-day moving average of $1.50.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.04 million. InflaRx had a negative return on equity of 47.03% and a negative net margin of 44,046.09%. As a group, equities research analysts forecast that InflaRx will post -0.98 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.